Bantam Pharmaceutical
@bantampharma.com
Bantam Pharmaceutical is a drug discovery and development company leveraging the power of mitochondrial dynamics to address critical unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is advancing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company currently holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell malignancies, with plans to expand clinical development into solid tumors. About BTM-3566 BTM-3566 is a novel, orally available small molecule designed to target a wide range of cancers, including both hematologic and solid tumors. Its initial clinical focus is on mature B-cell lymphomas, such as mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). In preclinical studies, BTM-3566 demonstrated potent anti-cancer activity, driving significant tumor regression – and in many cases, complete tumor elimination – in models resistant to standard treatments, including CAR-T cell therapy. BTM-3566 works by disrupting the mitochondrial function in tumor cells, triggering their natural cell death process (apoptosis). With its unique mechanism of action and strong preclinical data, Bantam also plans to expand clinical development into solid tumors, broadening its potential impact for patients with limited treatment options.
Bantam Pharmaceutical's Company Logos
Bantam Pharmaceutical's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#5214A3
Blue Gem
82, 20, 163
266, 78, 36
50, 88, 0, 36
#1E478F
Blumine
30, 71, 143
218, 65, 34
79, 50, 0, 44
#F8C34E
Casablanca
248, 195, 78
41, 92, 64
0, 21, 69, 3
About Bantam Pharmaceutical
Bantam Pharmaceutical is a forward-looking biotechnology company based in Research Triangle Park, North Carolina, established in 2015. Committed to revolutionizing cancer treatment, Bantam specializes in developing innovative oral small molecule therapeutics aimed primarily at addressing difficult-to-treat hematological and solid tumors. Their flagship compound, BTM-3566, is designed to target a range of malignancies, with initial clinical trials focused on mature B-cell lymphomas such as mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.
Leveraging unique insights into mitochondrial dynamics, Bantam's strategy encompasses both advancing BTM-3566 into clinical settings and exploring the discovery of additional small molecules with oncological applications. The company is dedicated to expanding its pipeline to address significant unmet medical needs within solid tumors, thereby enhancing potential treatment options for patients. Bantam is actively seeking partnerships and investments to expedite the development of its pioneering therapies and is poised to make a substantial impact in the oncology field.
